BRD2 and myeloid sarcoma: In our study, 38% of the RRMS patients experienced clinical reactivation of the MS, 83% suffered from a relapse during the first 6 months after NAT withdrawal which confirms data from previous studies in which the proportion of patients with relapses post NAT has ranged from 9 to 80% (43).